Advertisement
Corrigendum
Open Access | 
10.1172/JCI168084
Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions
Nan Chiang, Stephania Libreros, Paul C. Norris, Xavier de la Rosa, and Charles N. Serhan
Find articles by Chiang, N. in: JCI | PubMed | Google Scholar
Find articles by Libreros, S. in: JCI | PubMed | Google Scholar
Find articles by Norris, P. in: JCI | PubMed | Google Scholar
Find articles by de la Rosa, X. in: JCI | PubMed | Google Scholar
Find articles by Serhan, C. in: JCI | PubMed | Google Scholar
Published January 17, 2023 - More info
J Clin Invest. 2023;133(2):e168084. https://doi.org/10.1172/JCI168084.
© 2023 functions et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Related article:
Abstract
Resolution of acute inflammation is an active process orchestrated by endogenous mediators and mechanisms pivotal in host defense and homeostasis. The macrophage mediator in resolving inflammation, maresin 1 (MaR1), is a potent immunoresolvent, stimulating resolution of acute inflammation and organ protection. Using an unbiased screening of greater than 200 GPCRs, we identified MaR1 as a stereoselective activator for human leucine-rich repeat containing G protein–coupled receptor 6 (LGR6), expressed in phagocytes. MaR1 specificity for recombinant human LGR6 activation was established using reporter cells expressing LGR6 and functional impedance sensing. MaR1-specific binding to LGR6 was confirmed using 3H-labeled MaR1. With human and mouse phagocytes, MaR1 (0.01–10 nM) enhanced phagocytosis, efferocytosis, and phosphorylation of a panel of proteins including the ERK and cAMP response element-binding protein. These MaR1 actions were significantly amplified with LGR6 overexpression and diminished by gene silencing in phagocytes. Thus, we provide evidence for MaR1 as an endogenous activator of human LGR6 and a novel role of LGR6 in stimulating MaR1’s key proresolving functions of phagocytes.
Authors
Nan Chiang, Stephania Libreros, Paul C. Norris, Xavier de la Rosa, Charles N. Serhan
Original citation: J Clin Invest. 2019;129(12):5294–5311. https://doi.org/10.1172/JCI129448
Citation for this corrigendum: J Clin Invest. 2023;133(2):e168084. https://doi.org/10.1172/JCI168084
The authors recently became aware that representative illustrations presented in Supplemental Figure 7A might be mistaken for original data. As this schematic was used strictly for demonstrative purposes, it has been removed from the figure for clarity. A tabular representation of the experimental findings is provided in Supplemental Table 3. The supplemental document has been updated online.
Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)